-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Alps Advisors Inc. Cuts Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)
Alps Advisors Inc. Cuts Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)
Alps Advisors Inc. trimmed its holdings in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Get Rating) by 42.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 88,224 shares of the biopharmaceutical company's stock after selling 64,538 shares during the quarter. Alps Advisors Inc. owned approximately 0.06% of Arbutus Biopharma worth $239,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. grew its holdings in Arbutus Biopharma by 8.9% in the second quarter. JPMorgan Chase & Co. now owns 64,191 shares of the biopharmaceutical company's stock worth $173,000 after purchasing an additional 5,265 shares during the last quarter. SG Americas Securities LLC grew its holdings in Arbutus Biopharma by 62.5% in the second quarter. SG Americas Securities LLC now owns 21,518 shares of the biopharmaceutical company's stock worth $58,000 after purchasing an additional 8,274 shares during the last quarter. Front Row Advisors LLC purchased a new position in Arbutus Biopharma in the first quarter worth $31,000. Principal Financial Group Inc. purchased a new position in Arbutus Biopharma in the second quarter worth $32,000. Finally, WMG Financial Advisors LLC purchased a new position in Arbutus Biopharma in the second quarter worth $34,000. 29.63% of the stock is owned by hedge funds and other institutional investors.
Get Arbutus Biopharma alerts:Analyst Ratings Changes
Several equities analysts have issued reports on ABUS shares. HC Wainwright cut their price target on shares of Arbutus Biopharma from $7.50 to $6.00 and set a "buy" rating on the stock in a report on Thursday, November 10th. StockNews.com started coverage on shares of Arbutus Biopharma in a report on Wednesday, October 12th. They issued a "hold" rating on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $6.50.
Arbutus Biopharma Price Performance
Shares of ABUS opened at $2.70 on Thursday. Arbutus Biopharma Co. has a 1-year low of $1.85 and a 1-year high of $6.50. The company's fifty day moving average price is $2.25 and its 200-day moving average price is $2.39.Arbutus Biopharma Company Profile
(Get Rating)
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication.
Read More
- Get a free copy of the StockNews.com research report on Arbutus Biopharma (ABUS)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
Want to see what other hedge funds are holding ABUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arbutus Biopharma Co. (NASDAQ:ABUS – Get Rating).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
Alps Advisors Inc. trimmed its holdings in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Get Rating) by 42.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 88,224 shares of the biopharmaceutical company's stock after selling 64,538 shares during the quarter. Alps Advisors Inc. owned approximately 0.06% of Arbutus Biopharma worth $239,000 as of its most recent SEC filing.
據Alps Advisors Inc.在提交給美國證券交易委員會的最新Form 13F文件中稱,該公司在第二季度減持了42.2%的Arbutus Biophma Co.股票。該公司在本季度出售了64,538股後,持有這家生物製藥公司88,224股股票。據最近提交給美國證券交易委員會的文件顯示,Alps Advisors Inc.擁有Arbutus Biophma約0.06%的股份,價值23.9萬美元。
Other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. grew its holdings in Arbutus Biopharma by 8.9% in the second quarter. JPMorgan Chase & Co. now owns 64,191 shares of the biopharmaceutical company's stock worth $173,000 after purchasing an additional 5,265 shares during the last quarter. SG Americas Securities LLC grew its holdings in Arbutus Biopharma by 62.5% in the second quarter. SG Americas Securities LLC now owns 21,518 shares of the biopharmaceutical company's stock worth $58,000 after purchasing an additional 8,274 shares during the last quarter. Front Row Advisors LLC purchased a new position in Arbutus Biopharma in the first quarter worth $31,000. Principal Financial Group Inc. purchased a new position in Arbutus Biopharma in the second quarter worth $32,000. Finally, WMG Financial Advisors LLC purchased a new position in Arbutus Biopharma in the second quarter worth $34,000. 29.63% of the stock is owned by hedge funds and other institutional investors.
其他機構投資者最近也買賣了該公司的股票。今年第二季度,摩根大通對Arbutus Biophma的持有量增加了8.9%。摩根大通(JPMorgan Chase&Co.)在上個季度增持了5,265股後,現在持有64,191股這家生物製藥公司的股票,價值173,000美元。第二季度,SG America Securities LLC對Arbutus Biophma的持有量增加了62.5%。SG America Securities LLC現在擁有這家生物製藥公司21,518股股票,價值58,000美元,此前在上個季度又購買了8,274股。Front Row Advisors LLC在第一季度購買了Arbutus Biophma的一個新頭寸,價值3.1萬美元。信安金融集團公司在第二季度購買了價值3.2萬美元的Arbutus Biophma的新頭寸。最後,WMG Financial Advisors LLC在第二季度購買了Arbutus Biophma的一個新頭寸,價值3.4萬美元。29.63%的股票由對衝基金和其他機構投資者持有。
Analyst Ratings Changes
分析師評級發生變化
Several equities analysts have issued reports on ABUS shares. HC Wainwright cut their price target on shares of Arbutus Biopharma from $7.50 to $6.00 and set a "buy" rating on the stock in a report on Thursday, November 10th. StockNews.com started coverage on shares of Arbutus Biopharma in a report on Wednesday, October 12th. They issued a "hold" rating on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $6.50.
幾位股票分析師已經發布了關於Abus股票的報告。在11月10日星期四的一份報告中,HC Wainwright將Arbutus Biophma的目標價從7.50美元下調至6.00美元,並對該股設定了“買入”評級。StockNews.com在10月12日星期三的一份報告中開始報道Arbutus Biophma的股票。他們對該股的評級為“持有”。一名分析師對該股的評級為持有,四名分析師對該股的評級為買入。根據MarketBeat.com的數據,該公司的共識評級為“適度買入”,共識目標價為6.50美元。
Arbutus Biopharma Price Performance
楊梅價格表現
Arbutus Biopharma Company Profile
楊梅公司簡介
(Get Rating)
(獲取評級)
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication.
Arbutus Biophma公司是一家生物製藥公司,在美國開發針對慢性乙肝病毒(乙肝)感染、SARS-CoV-2和其他冠狀病毒的新療法。該公司的乙肝病毒產品線包括AB-729,這是一種專利的候選皮下遞送RNA幹擾產品,在Ia/Ib期臨牀試驗中針對肝細胞,利用新型共價結合N-乙酰半乳糖胺(GalNAc)遞送技術抑制病毒複製,並減少多種乙肝抗原;以及AB-836,一種口服衣殼抑制物,用於抑制HBVDNA複製。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Arbutus Biopharma (ABUS)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
- 免費獲取StockNews.com上關於楊樹的研究報告(ABUS)
- 60/40的投資組合組合還在《時尚》雜誌上流行嗎?
- 機構對ADI的支持仍然很高
- 微軟股票:是時候備份卡車了嗎?
- Salesforce裁員,儘管面臨挑戰,但收入強勁
- 三隻CBD股票將主宰一個萌芽行業
Want to see what other hedge funds are holding ABUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arbutus Biopharma Co. (NASDAQ:ABUS – Get Rating).
想看看其他對衝基金持有什麼嗎?訪問HoldingsChannel.com獲取Arbutus Biophma Co.(納斯達克代碼:ABUS-GET Rating)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《楊梅日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Arbutus Biophma和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧